47
Participants
Start Date
January 31, 2008
Primary Completion Date
July 31, 2010
Study Completion Date
July 31, 2010
Erlotinib and Dasatinib
You will begin study drug regimen on day 1 of cycle 1 w Dasatinib. If you are undergoing Dasatinib pharmacokinetic blood analysis, Dasatinib will be taken alone until initial PK assessments are collected. Erlotinib will be begin after initial Dasatinib PK assessments are collected \& will continue to be administered w Dasatinib on continuous daily dosing schedule. Initial Dasatinib PK assessments will be collected over 24hrs between days 3-7 of cycle 1 \& at end of cycle 1. If you are not undergoing Dasatinib PK collections you will begin both Dasatinib \& Erlotinib together on day 1 of cycle 1. Both drugs will be given in continuous daily oral manner. Cycle is defined as Dasatinib \& Erlotinib given daily for 28 days for purpose of scheduling evaluations.
Duke University Health System, Durham
Lead Sponsor
Collaborators (2)
Bristol-Myers Squibb
INDUSTRY
Genentech, Inc.
INDUSTRY
Duke University
OTHER